Treatment | Exudate Volume | Cells | NOx | PGE2 | LTB4 | TNF-α | n |
---|---|---|---|---|---|---|---|
mg/kg/p.o. | ml | ×106 | μg | ng | ng | ng | |
Control | 0.70 ± 0.03 | 126.6 ± 5.6 | 1.51 ± 0.06 | 0.428 ± 0.01 | 2.50 ± 0.15 | 2.14 ± 0.17 | 35 |
Roxithromycin | |||||||
10 | 0.65 ± 0.05 | 119.8 ± 5.6 | 1.58 ± 0.04 | 0.410 ± 0.06 | 2.54 ± 0.15 | 1.81 ± 0.11 | 9 |
20 | 0.45 ± 0.09** | 101.3 ± 6.11-150 | 0.99 ± 0.07*** | 0.338 ± 0.031-150 | 2.30 ± 0.14 | 1.32 ± 0.111-150 | 8 |
40 | 0.35 ± 0.1*** | 88.5 ± 7.5** | 0.75 ± 0.03*** | 0.253 ± 0.03*** | 2.15 ± 0.25 | 1.13 ± 0.08** | 7 |
Clarithromycin | |||||||
10 | 0.75 ± 0.09 | 123.0 ± 7.9 | 1.44 ± 0.10 | 0.399 ± 0.06 | 2.60 ± 0.12 | 1.99 ± 0.13 | 7 |
20 | 0.55 ± 0.12 | 107.6 ± 8.9 | 1.18 ± 0.071-150 | 0.329 ± 0.041-150 | 2.40 ± 0.11 | 1.54 ± 0.201-150 | 9 |
40 | 0.4 ± 0.08** | 88.2 ± 11** | 0.88 ± 0.05*** | 0.244 ± 0.03*** | 2.03 ± 0.21 | 1.13 ± 0.12** | 9 |
Erythromycin | |||||||
10 | 0.65 ± 0.08 | 123.9 ± 2.9 | 1.39 ± 0.05 | 0.401 ± 0.04 | 2.37 ± 0.12 | 1.92 ± 0.07 | 9 |
20 | 0.60 ± 0.10 | 93.6 ± 8.31-150 | 1.07 ± 0.11** | 0.261 ± 0.06*** | 2.12 ± 0.28 | 1.52 ± 0.081-150 | 8 |
40 | 0.35 ± 0.05*** | 86.6 ± 6.3** | 0.85 ± 0.04*** | 0.201 ± 0.02*** | 1.87 ± 0.27 | 1.03 ± 0.10** | 8 |
Azithromycin | |||||||
10 | 0.65 ± 0.04 | 122.8 ± 4.8 | 1.34 ± 0.14 | 0.412 ± 0.06 | 2.47 ± 0.22 | 2.17 ± 0.08 | 7 |
20 | 0.65 ± 0.03 | 105.0 ± 8.1 | 1.14 ± 0.22 | 0.347 ± 0.05 | 2.25 ± 0.30 | 1.91 ± 0.08 | 9 |
40 | 0.65 ± 0.06 | 102.5 ± 6.21-150 | 1.05 ± 0.091-150 | 0.325 ± 0.051-150 | 2.07 ± 0.35 | 1.38 ± 0.17** | 8 |
Indomethacin | |||||||
5 | 0.19 ± 0.01*** | 87.3 ± 7.51-150 | 0.98 ± 0.091-150 | 0.05 ± 0.01*** | 2.35 ± 0.1 | 4.1 ± 0.18*** | 8 |
Results are given per rat (mean ± S.E.).
↵1-150 P < .05, ** P < .01, *** P < .001 versus control.